BR112021026916A2 - Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina - Google Patents
Métodos de tratamento de hiv em pacientes pediátricos com rilpivirinaInfo
- Publication number
- BR112021026916A2 BR112021026916A2 BR112021026916A BR112021026916A BR112021026916A2 BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2 BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2
- Authority
- BR
- Brazil
- Prior art keywords
- rilpivirine
- methods
- pediatric patients
- treating hiv
- pediatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870413P | 2019-07-03 | 2019-07-03 | |
| PCT/EP2020/068734 WO2021001508A1 (en) | 2019-07-03 | 2020-07-02 | Methods of treating hiv in pediatric patients with rilpivirine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026916A2 true BR112021026916A2 (pt) | 2022-05-10 |
Family
ID=71579550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026916A BR112021026916A2 (pt) | 2019-07-03 | 2020-07-02 | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina |
| BR112021026739A BR112021026739A2 (pt) | 2019-07-03 | 2020-07-03 | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026739A BR112021026739A2 (pt) | 2019-07-03 | 2020-07-03 | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina |
Country Status (14)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| NZ610729A (en) * | 2010-11-19 | 2015-10-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| EP4233846B1 (en) * | 2015-06-30 | 2024-12-04 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| MA46563B1 (fr) * | 2016-10-24 | 2024-01-31 | Janssen Sciences Ireland Unlimited Co | Compositions dispersibles |
| RU2755710C2 (ru) * | 2017-06-30 | 2021-09-20 | Вайв Хелткер Компани | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
| MA56449A (fr) * | 2019-07-03 | 2022-05-11 | Janssen Sciences Ireland Unlimited Co | Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine |
-
2020
- 2020-07-02 MA MA056449A patent/MA56449A/fr unknown
- 2020-07-02 EP EP20739584.9A patent/EP3993799A1/en active Pending
- 2020-07-02 JP JP2021577856A patent/JP2022538338A/ja not_active Withdrawn
- 2020-07-02 MX MX2022000060A patent/MX2022000060A/es unknown
- 2020-07-02 AU AU2020300818A patent/AU2020300818A1/en not_active Abandoned
- 2020-07-02 CN CN202080048751.4A patent/CN114126655A/zh active Pending
- 2020-07-02 KR KR1020227003258A patent/KR20220028049A/ko not_active Withdrawn
- 2020-07-02 BR BR112021026916A patent/BR112021026916A2/pt unknown
- 2020-07-02 WO PCT/EP2020/068734 patent/WO2021001508A1/en not_active Ceased
- 2020-07-02 US US16/919,677 patent/US20210000823A1/en not_active Abandoned
- 2020-07-03 MX MX2021015627A patent/MX2021015627A/es unknown
- 2020-07-03 BR BR112021026739A patent/BR112021026739A2/pt unknown
- 2020-07-03 EP EP20742659.4A patent/EP3993800A1/en active Pending
- 2020-07-03 WO PCT/EP2020/068913 patent/WO2021001568A1/en not_active Ceased
- 2020-07-03 KR KR1020227003246A patent/KR20220028048A/ko not_active Withdrawn
- 2020-07-03 CN CN202080048752.9A patent/CN114080223A/zh active Pending
- 2020-07-03 JP JP2021577871A patent/JP2022538449A/ja not_active Withdrawn
- 2020-07-03 PH PH1/2021/553288A patent/PH12021553288A1/en unknown
- 2020-07-03 AU AU2020300033A patent/AU2020300033A1/en not_active Abandoned
- 2020-07-03 US US17/621,759 patent/US20220313693A1/en active Pending
- 2020-07-03 MA MA056453A patent/MA56453A/fr unknown
- 2020-07-03 CA CA3144307A patent/CA3144307A1/en active Pending
-
2021
- 2021-12-28 IL IL289457A patent/IL289457A/en unknown
- 2021-12-30 JO JOP/2021/0347A patent/JOP20210347A1/ar unknown
-
2024
- 2024-01-10 US US18/408,900 patent/US20240139186A1/en active Pending
-
2026
- 2026-02-05 JP JP2026018065A patent/JP2026097814A/ja active Pending
- 2026-02-05 JP JP2026018074A patent/JP2026097815A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021001568A1 (en) | 2021-01-07 |
| MA56449A (fr) | 2022-05-11 |
| MX2021015627A (es) | 2022-04-25 |
| CN114126655A (zh) | 2022-03-01 |
| JP2026097814A (ja) | 2026-06-16 |
| CN114080223A (zh) | 2022-02-22 |
| CA3144307A1 (en) | 2021-01-07 |
| EP3993799A1 (en) | 2022-05-11 |
| JP2022538449A (ja) | 2022-09-02 |
| JP2022538338A (ja) | 2022-09-01 |
| MX2022000060A (es) | 2022-04-18 |
| JP2026097815A (ja) | 2026-06-16 |
| KR20220028048A (ko) | 2022-03-08 |
| US20220313693A1 (en) | 2022-10-06 |
| CA3144534A1 (en) | 2021-01-07 |
| KR20220028049A (ko) | 2022-03-08 |
| AU2020300818A1 (en) | 2022-03-03 |
| BR112021026739A2 (pt) | 2022-04-26 |
| EP3993800A1 (en) | 2022-05-11 |
| US20240139186A1 (en) | 2024-05-02 |
| PH12021553288A1 (en) | 2022-08-01 |
| US20210000823A1 (en) | 2021-01-07 |
| WO2021001508A1 (en) | 2021-01-07 |
| IL289457A (en) | 2022-02-01 |
| MA56453A (fr) | 2022-05-11 |
| JOP20210347A1 (ar) | 2023-01-30 |
| AU2020300033A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| BR112018016341A2 (pt) | solução de bloqueio do cateter e terapia de bloqueio do cateter | |
| EA202191133A1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| BR112018069776A2 (pt) | tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23 | |
| BR112019005944A2 (pt) | anticorpos que se ligam à interleucina 2 e usos dos mesmos | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| ZA202300222B (en) | Anti-αlpha-4-βeta-7 antibodies | |
| CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
| BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica | |
| BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
| MY202382A (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| MX2021015448A (es) | Células linfocíticas activadas y métodos para usarlas para tratar cáncer y afecciones infecciosas. | |
| PH12022552499A1 (en) | Technologies for preventing or treating infections | |
| PH12015501574A1 (en) | Diposable diaper | |
| BR102018068947A8 (pt) | sistemas de instrumento cirúrgico ortopédico específicos para um lado do corpo e métodos de uso associados | |
| BR112021020962A2 (pt) | Métodos de tratamento de prurido | |
| BR112021026739A2 (pt) | Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina | |
| BR112021005759A2 (pt) | composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo | |
| CO2025004675A2 (es) | Método para tratar vih con cabotegravir y rilpivirina en pacientes pediátricos | |
| BR112022026126A2 (pt) | Formulações | |
| BR112019004838A2 (pt) | tratamento de linfoma não-hodgkin usando lilotomab e 177lu-lilotomab satetraxetan | |
| EA201891922A1 (ru) | Лекарственное средство для лечения инфекций на фоне диабетической стопы | |
| MX394902B (es) | Secuelas de lesión pulmonar inducida por baipás cardiopulmonar. | |
| MX2020002485A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |